This week concludes Saama’s Clinical Trial Excellence for Tomorrow and Beyond blog series, each installment of which has been authored by one of our six new Clinical Board of Advisor members. In this final post, Jay Kaminski, Chief Operating Officer at Celularity and former Senior Vice President of Global Clinical Research & Development Operations at Celgene Corporation, explores the challenges and considerations that are unique to biotechnology clinical trials, and how data analytics can help address those issues.
Biotech and pharma share many of the same challenges when it comes to clinical trials, including common bottlenecks involving patient identification and recruitment, investigator and site start-up, protocol design and trial feasibility assessments. Biotech and pharma also share another distinction – access to unprecedented amounts of data to inform clinical development.
Cost Considerations: Big Data Analytics for Clinical Trials in Biotech Print
Modified on: Mon, 8 Feb, 2021 at 2:20 PM
Did you find it helpful? Yes No
Send feedbackSorry we couldn't be helpful. Help us improve this article with your feedback.